Skip to main content
Premium Trial:

Request an Annual Quote

BioGx Gets CE Marking for Six Meningitis, Antibiotic Resistance Tests

NEW YORK (GenomeWeb) – BioGx announced today that it has received CE marking for six tests for various meningitis infections and antibiotic-resistant organisms.

The tests are designed to run on Becton Dickinson's PCR-based BD Max platform. The meningitis tests cover viral meningitis based on DNA from HSV-1, HSV-2, and VZV; bacterial meningitis based on DNA from Neisseria meningitidis, Streptococcus pneumoniae, and Haemophilus influenzae; and bacterial meningitis ELGBS based on DNA from Escherichia coliListeria spp., and Group B Streptococcus.

The antibiotic resistance tests include ones for carbapenem resistance in organisms with the resistance genes KPC, NDM-1, and OXA-48; carbapenem and colistin resistance in organisms with the resistance genes VIM, GES, and mcr-1; and vancomycin resistance in organisms with the resistance genes vanA, vanB, vanC1, and vanC2/3.

Birmingham, Alabama-based BioGx now has 11 CE-marked tests that run on the BD Max system — including ones for influenza A, influenza B, respiratory syncytial virus, mycoplasma/ureaplasma genital infections, Pneumocystis jirovecii infection, tuberculosis, and Bordetella infection — and expects to receive CE marking on an additional 10 before the end of the year.

The Scan

Genetic Risk Factors for Hypertension Can Help Identify Those at Risk for Cardiovascular Disease

Genetically predicted high blood pressure risk is also associated with increased cardiovascular disease risk, a new JAMA Cardiology study says.

Circulating Tumor DNA Linked to Post-Treatment Relapse in Breast Cancer

Post-treatment detection of circulating tumor DNA may identify breast cancer patients who are more likely to relapse, a new JCO Precision Oncology study finds.

Genetics Influence Level of Depression Tied to Trauma Exposure, Study Finds

Researchers examine the interplay of trauma, genetics, and major depressive disorder in JAMA Psychiatry.

UCLA Team Reports Cost-Effective Liquid Biopsy Approach for Cancer Detection

The researchers report in Nature Communications that their liquid biopsy approach has high specificity in detecting all- and early-stage cancers.